TCR² Therapeutics to Present at the Truist Securities Life Sciences Summit

Rhea-AI Summary

CAMBRIDGE, Mass., April 29, 2021 - TCR² Therapeutics (Nasdaq: TCRR), a clinical-stage cell therapy company, will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, at 11:20 AM E.T. The event will be held virtually, and a live webcast will be accessible on the Company’s Investors page. TCR² focuses on developing novel T cell therapies targeting solid tumors and hematological malignancies, including gavo-cel for mesothelin-positive cancers and TC-110 for CD19-positive leukemias.

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021 at 11:20am E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR² Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com

FAQ

What is TCRR participating in on May 5, 2021?

TCRR will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit.

Where can I watch the TCRR fireside chat?

You can watch the TCRR fireside chat live on their Investors page at www.investors.tcr2.com.

What are the lead product candidates of TCRR?

TCRR's lead candidates are gavo-cel for solid tumors and TC-110 for hematological malignancies.

What type of company is TCRR?

TCRR is a clinical-stage cell therapy company developing T cell therapies for cancer.

How does TCRR's therapy differ from CAR-T cells?

TCRR's TRuC-T cells demonstrate superior anti-tumor activity and lower cytokine release compared to CAR-T cells.